Intake of high-intensity statin after acute myocardial infarction assessed by direct drug concentration measurement: association with LDL-C response and coronary plaque modifications in the PACMAN-AMI trial.
Vera van der Velpen, Jonas D Häner, Ryota Kakizaki et al.
✦ AI-curated · Sources linked
In 30 seconds
The PACMAN-AMI randomized controlled trial assessed adherence to high-intensity statin therapy in 300 patients post-acute myocardial infarction. Results showed that 1.3% reported statin intolerance, with adherent patients experiencing a significant LDL-C reduction of -2.73 mmol/L compared to +0.07 mmol/L in non-adherent patients at 52 weeks. This study highlights the importance of medication adherence in cardiovascular outcomes.
Key findings
- 1.3% of patients reported statin intolerance within 52 weeks.
- Adherent patients had a reduction in LDL-C of -2.73 mmol/L compared to +0.07 mmol/L for non-adherent patients.
- Adherent patients showed a -1.54% change in atheroma volume versus -0.15% in non-adherent patients.
- Fibrous cap thickness increased by +48.53 µm in adherent patients compared to +7.98 µm in non-adherent patients.
Why it matters
Understanding adherence to statin therapy is crucial for improving cardiovascular outcomes post-myocardial infarction. This study reinforces the need for monitoring medication intake to optimize treatment efficacy and patient health.